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Abstract
This study was initiated to identify biomarkers with potential value for the early detection of poor-outcome breast cancer. Two
sets of well-characterized tissues were utilized: one from breast cancer patients with favorable vs. poor outcome and the other
from healthy women undergoing reduction mammaplasty. Over 46 differentially expressed genes were identified from a large
list of potential targets by a) mining publicly available expression data (identifying 134 genes for quantitative PCR) and b)
utilizing a commercial PCR array. Three genes show elevated expression in cancers with poor outcome and low expression in all
other tissues, warranting further investigation as potential blood markers for early detection of cancers with poor outcome.
Twelve genes showed lower expression in cancers with poor outcome than in cancers with favorable outcome but no
differential expression between aggressive cancers and most healthy controls. These genes are more likely to be useful as
prognostic tissue markers than as serum markers for early detection of aggressive disease. As a secondary finding was that,
when histologically normal breast tissue was removed from a distant site in a breast with cancer, 7 of 38 specimens displayed a
cancer-like expression profile, while the remaining 31 were genetically similar to the reduction mammaplasty control group.
This finding suggests that some regions of ipsilateral histologically ‘normal’ breast tissue are predisposed to becoming
malignantandthatnormal-appearingtissuewithmalignantsignaturemightwarranttreatmenttopreventnewprimarytumors.
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Introduction
Our goal in this study was to identify biomarkers with potential
value for the early detection of poor-outcome breast cancer. In
1999 we successfully used a transcript-based discovery approach to
identify early detection markers for ovarian cancer [1]. Following
the 5 phases of screening biomarker development proposed by
Pepe et al. [2], HE4, the product of the human epididymis gene
WFDC2, was developed into a serum assay [3,4] that is now
approved for remission monitoring of ovarian cancer. It is being
evaluated for its potential role in screening and is considered a
successful product of translational biomarker research.
Because breast cancer marker research has focused mainly on
prognosis [5], there are few comprehensive studies to identify early
detection markers. We therefore relied on our previously successful
approach using gene discovery by cDNA microarray followed by
expression validation through polymerase chain reaction (PCR),
ranking of potential markers and the development and testing of
serum assays. For breast cancer, a large body of research already
available in the public domain allowed us to forego our own
microarray work; instead we mined publicly available expression
data in tissues of breast cancer and normal healthy controls.
One of the lessons learned from previous gene discovery
experiments is the importance of having high-quality appropri-
ately preserved specimens and matching patient data. We
therefore spent considerable effort on the accrual of needed
tissues. In close collaboration with participating surgeons and
pathologists, we were able to collect specimens in the operating
and gross rooms where they were processed with as little delay as
possible, thus minimizing variability. In addition, routine clinical
gross and microscopic tissue analysis was complemented with
routine research histological examination on the actual tissue piece
that was later used for expression analysis. Breast tissues from
breast cancer patients were then compared to those from healthy
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9122individuals. While normal tissue adjacent to the cancer is relatively
easy to obtain, we feared that in cancer patients, cancer-related
pathways may be perturbed in these tissues [6]. We therefore used
normal tissue from breast reduction mammaplasties as controls.
We identified a few genes meeting necessary criteria for
potential development as serum markers for diagnosis or early
detection of poor-outcome breast cancer. In addition we identified
several genes with potential to guide prognosis and therapy.
Results and Discussion
Our goal was to identify tissue markers that differentiate
between healthy breast tissues and breast cancer tissue from
patients with poor outcome. This was done in a series of successive
steps: Establishment of the range of expression of genes in healthy
breast tissue; database mining to identify potential genes with
differential expression between breast cancers and controls;
expression validation of these genes in breast cancer tissues and
controls; and identification of those genes with over-expression in
cancers with poor outcome relative to both good-outcome cancer
and healthy control tissue.
Determination of Components of Variation of Normal
Tissue
The primary goal was to identify genes that discriminate
between normal breast tissue and invasive carcinoma of the breast.
Since normal breast tissue was to be used as a reference, a
threshold needed to be determined above which a gene would be
labeled as differentially expressed. Therefore we assessed the
variability in gene expression within normal breast tissue To our
knowledge, this has not previously been well studied. Quantitative
PCR (SYBR) expression analysis was performed for 18 genes on
an average of 3.5 tissue slices per breast from 10 women with
bilateral reduction mammaplasty. The PCRs were normalized by
their median and the duplicate runs were averaged. Table 1 shows
overall gene expression variability (as standard deviation) and
which fraction of it is attributable to the component variabilities of
woman-to-woman (averaging 64%69%), within-breast (averaging
30%69%) and left-to-right breast (averaging 6%63%). These
percentages represent the overall magnitude of the different
sources of variation as determined by ANOVA analyses. As
expected, between-woman variability is greatest, twice that of
within-breast variability, implying that the largest source of
variation is heterogeneity among women. Approximately 30% of
overall variation was explained by variation in the molecular
behavior of different tissue specimens of the same breast (note the
assays were performed in duplicate, and the coefficient of variation
(CV) of the assay was small compared to each of these components
of variation and so can be ignored). The smallest source of
variation is the between-breast component, implying that normal
material from a contralateral breast is a good surrogate for normal
material from the affected breast. Note that the 30% within- and
6% between-breast variation does not imply that two biopsies from
different breasts are more similar than two biopsies from the same
Table 1. Variability in gene expression.
Proportion of Standard Deviation
Marker StDev Between women Within breast
Between breasts (same
woman)
ASPN 0.88 75% 21% 3%
CAV1 0.89 60% 38% 2%
CFB 0.74 46% 46% 8%
COL1A2 1.13 76% 15% 10%
CTGF 1.07 67% 28% 6%
GATA3 1.61 60% 36% 4%
LETMD1 0.46 79% 11% 9%
MGST1 0.94 59% 37% 4%
LYZ 1.08 66% 23% 8%
MMP2 0.63 50% 39% 10%
MUC1 2.34 62% 34% 4%
SPARC 0.71 74% 22% 3%
SUMF2 0.39 55% 35% 7%
TIMP1 0.69 65% 26% 9%
TIMP2 0.49 63% 29% 7%
TIMP3 0.60 67% 30% 3%
WFDC2 2.73 61% 35% 4%
YWHAZ 0.37 64% 30% 5%
Mean 64% 30% 6%
StDev 9% 9% 3%
Variability in healthy breast tissue from non-cancer patients measured in 18 genes by ANOVA. The Standard Deviation (StDev) stands for the variability of each
individual gene across all tissue specimens. The third column shows the proportion of the standard deviation attributed to differences between women. The fourth
column shows the standard deviation attributed to differences within one breast of an individual woman and the last column shows the additional proportion of
standard deviation due to the variability between both breasts of the same woman. The overall mean proportion of variability by individual woman is 30% plus 6%.
doi:10.1371/journal.pone.0009122.t001
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across breasts will have a standard deviation that is only 6% larger
than the histogram within a breast (the 6% refers to the excess
variation when sampling across breasts). Because each value was
median-centered, the standard deviation also represents a
surrogate for CV in the population; it is scaled to the typical
expression levels. Six of the 18 genes have standard deviations
above 1 (COL1A2, CTGF, GATA3, LYZ, MUC1 and WFDC2) that
could be related to a spotty expression pattern (e.g. only a few cells
in a tissue express the transcript). Of note, this elevated variability
is unrelated to within-breast variability. For WFDC2, the gene with
the highest variability across all tissue specimens, the standard
deviation is 2.73. Therefore, for subsequent comparisons of
expression in cancer to that in healthy normal tissue, a threshold
will be chosen consisting of the mean expression in healthy breast
mammaplasty tissue plus 3 standard deviations (viz. 8.19 for
WFDC2). The same calculation will be done for each gene.
Database Mining Identifies Genes with Differential
Expression between Breast Cancer and Normal Tissues
Despite a large body of research on gene and protein expression
in breast cancer, few studies include healthy controls. In those that
do [7,8,9,10,11,12,13,14,15,16], the control tissues are often not
well characterized. Most publications report expression only in
breast cancer and not in healthy controls. However, these are still
useful for a cancer-to-normal comparison since their data can
potentially be matched with those from other sources using healthy
normal tissues. A sizable number of these breast publications use
large-scale analysis, such as microarrays. These and additional
expression data were compiled in a database (LevelsDB) that was
then mined starting with genes contained in breast cancer data sets
(4405 genes), followed by removal of genes and proteins whose
subcellular localization makes the protein unlikely to be found in
the blood stream by non-necrotic processes (confirmed nuclear,
mitochondrial and ribosomal expression), leaving 3271. In a next
step, housekeeping genes were excluded, followed by removal of
genes with high levels of expression in normal tissues of organs
with high cardiac output [17,18,19] (expression greater than 10
times the median in bone, brain, heart, kidney, lung, liver, skeletal
muscle and pancreas). We rationalize that proteins can potentially
be produced at base level in many cells and that big organs (with
high cardiac output) may contribute more than others to a basic
blood protein level. The higher a basic blood protein level, the
harder it is to detect the excess protein made by the developing
tumor. From the remaining 1290 genes and proteins we retained
those with low expression in normal tissues. The lack of truly
normal breast expression data, except for data from one normal
tissue coming from a breast with cancer [20] required the use of
other normal, especially epithelial tissues for subtractive compar-
ison, contained in six datasets in LevelsDB. The last reduction step
resulted in 150 genes and proteins of which 44 were likely to be
secreted or membrane bound which makes them ideal as a blood
marker. These were augmented by 90 genes for which literature
review suggests a potential role as breast cancer markers, resulting
in 134 genes (Table 2) for subsequent expression analysis by PCR.
References for these additional genes are listed in the supplemental
Document S1.
Expression Validation Results in 46 Differentially
Expressed Genes
To identify from the 134 genes those with the ability to
discriminate between normal and malignant breast tissue, PCR
expression analysis was performed on 93 tissues (24 invasive
cancers, 38 ipsilateral normals, 3 contralateral normals, 28 tissues
from breast reduction surgery) from 64 women (Supplemental
Tables S1 and S2). The cDNA was oligo-dT primed. A comma-
delimited file with the expression data is available in the
supplemental document S2. PCR results for 8 genes were not
conclusive even after 2 repeats and the genes were removed from
further analysis (supplemental Table S3). Of the 126 remaining
genes, 67 discriminated between the 25 cancer tissues and the 28
mammaplasty controls with $20% of the cancers and #5% of the
controls above or below threshold (Table 2, and supplemental
Table S3).
After completion of the PCR work, a new PCR-based
technology (OpenArray by BioTrove, Woburn, MA) had come
to the market that allowed for more rapid gene expression analysis
[21]. This technology was used to confirm the expression of a
Table 2. 71 of 126 genes discriminate cancers from controls.
ADAM12* CSNK2A1 MIF SCGB2A1
AGR2* CTGF V MMP1 D SCUBE2* V
AKT1 CTHRC1* D MMP10 D SDC1
AMBP* CYP4B1* V MMP11 D SFRP1 V
ANGPT2* V CYR61 V MMP12 D SFRP2*
APOL1* V DEFA1 MMP13 D SNIP
AR V DEFA3 MMP14 SPARC V
ASPN* D ECM1* MMP16 SPP1 D
BGN* D EGFR V MMP2 V STC2*
BIRC5 D EPO MMP20 SUMF2*
BRCA2 EPOR V MMP3 THBS2
BRMS1 ERBB3* MMP7 V TIMP1 D
BUB1 D ERBB4 V MMP8 TIMP2 V
C18orf8* ESR1 D MMP9 TIMP3 V
CALB2 ETAA1* V MSLN TIMP4 V
CAV1 V FGFR2* V MUC1 D TK1 D
CCNE1 D FN1* D NES V TM9SF2*
CD274 D FOXA1 D OAS1* TNFRSF10B V
CD44 V GATA3 D OAS2* D TNN V
CDH1 GDF15 PEBP1 V TOP2A D
CDKN1B* V HOXB7 V PEBP4 TP53
CDX2 IFIT1* PGR V TRPS1
CFB* D IGF2 PIK3CA TTF1
COL11A1* D KRT20 PIP VCAN* D
COL1A1* D KRT7 PLAUR D VEGFA
COL1A2* D LCN2 PRLR* VTCN1
COL3A1* LETMD1 V PROCR V WFDC2 D
COL5A1* D LPAR3 PSMA5* WT1 D
COL5A2* V LRRC15* D PTPN1* XBP1
COL6A3* LTF* PVRL4 YWHAZ
COL8A1* LYZ* S100A7 D
COMP* D MGST1 V S100B* V
126 genes found by mining of expression data and/or LevelsDB (asterisk).
Thresholds for cancers and controls were determined by expression in the 28
normal mammaplasty tissues as mean +3 SD for genes with over-expression in
the cancers and as below the minimum for genes with under-expression in the
cancers. Over- (D) or under- (V) expression in cancer tissue with $20% of the
cancers and #5% of the controls above or below threshold.
doi:10.1371/journal.pone.0009122.t002
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Pathways OpenArray plate included primer pairs specific for 606
genes associated with DNA repair, angiogenesis, cell adhesion,
apoptosis, cell cycle and many genes encoding kinases. Of the 134
genes from database mining, 41 overlapped with the OpenArray
panel which was suitable for confirmation of about 30% of the
original results. Out of the 94 tissues that were originally tested, 13
were randomly selected from the 24 cancer tissues and likewise 9
from the 28 mammaplasty controls. Applying the same criteria as
for the original set, the OpenArray analysis of the reduced set
selected the same differentially expressed genes as the analysis of
the original set (supplemental Table S4). Both amplifications had
good correlation (supplemental Table S5) with an averaged
coefficient of variation of 38% (12%–71%), even considering the
differences between both methods (oligo-dT versus random
priming; differences in primer sequences).
Unsupervised cluster analysis of the 93 tissues and 67 genes
shows that 46 genes have the power to separate cancer tissues from
controls, thus confirming the validity of our approach (Figure 1,
red and green bars in the left). The mammaplasty control patients,
seen in Los Angeles, were on average 15 years younger than the
patients with tumor or ipsi- and contralateral normal tissue, seen
in Seattle. While differences in institution and age could
potentially introduce bias, the interspersing of the normal tissues
in the control cluster suggests that this is not the case (Figure 1).
This can be attributed in part to the strict adherence to identical
specimen collection protocols at both sites. No clustering behavior
was found based on other factors listed in the supplemental Table
S1, including mammography (BI-RADS) score and breast density
at the last mammogram before diagnosis, lymph node positivity,
tumor size, number of foci, stage and grade.
This first outcome from our analysis was 46 genes that show
differential expression between cancers and healthy breast tissues.
Having applied a similar strategy to discover serum markers for
ovarian cancer ([1,2,3,4]), we have reason to believe that these 46
genes have similar potential because our mining procedure
favored proteins with expression outside of the cell and with low
potential of being secreted at high level by other healthy tissue.
Once proven to be differentially expressed as serum proteins, it
will need to be investigated whether a marker could complement
mammography in early detection.
Comparison to Previously Published Results
Comparing the present gene expression results to those
previously published is difficult because prior studies rarely used
healthy normal controls. While the terms ‘‘over-’’ and ‘‘under-
expression’’ are common in the breast cancer literature, they most
often refer to expression of one cancer state relative to another or
to a cell line, and not relative to a healthy normal control. The
three breast cancer publications that used mammaplasty tissue as
controls confirm the expression pattern of the metalloproteinases
[22], YWHAZ [6], ERBB3 and ERBB4 [23]. Furthermore COL1A1
and COL1A2 over-expression was also seen in a meta-analysis of 13
publications comparing breast cancer to largely undefined and
probably ipsilateral normal tissue [24]. This gives credence to the
observed expression pattern of the remaining genes.
Identification of Additional Differentially Expressed
Genes
The OpenArray Cancer Pathways chip contained 606 genes of
which 41 were used for confirmation of the PCR results.
Unsupervised cluster analysis of the remaining 565 genes in the
13 cancers and 9 control tissue results in a clear distinction
between over- and under-expressed genes. The OpenArray PCR
was not duplicated and thus the results have greater error margins.
Therefore more stringent filtering conditions were applied than for
the original PCR: genes with differential expression in more than
30% of the tumors at a tumor-to-normal ratio of 1.2 were removed
from the dataset. Of the resulting 102 genes, 88% were found to
be under-expressed in the tumor tissues (see supplemental Figure
S1), as indicated by the negative %CV numbers in Table 3. Once
confirmed in their expression, it is likely that some of these 102
genes will be added to the 46 potential markers.
The high number of under-expressed genes contrasts sharply
with above results where over- and under-expressed genes are
equally represented. The Cancer Pathways genes had been
selected based on general cancer literature which includes a large
number of within-cancer and cell line experiments. Our data
mining on the other hand focused on breast cancer, normal-to-
cancer differences and extracellular expression. Hence, the former
contains a larger number of intracellular, regulatory proteins.
Interestingly, the differentially expressed genes in both sets are
enriched for connective tissue genes, suggesting that alteration in
the composition of the connective tissue is an important factor in
cancer formation.
Identification of Markers for Cancers with Poor Outcome
Unsupervised cluster analysis of the original PCR data resulted
in a cancer cluster with two sub-clusters, one enriched for patients
with cancers of the luminal subtype and one of the basal subtype,
as defined by hormone receptor and HER2 expression [25]
(Figure 1). Removing the normal tissues from analysis does not
alter this clustering behavior (Supplemental Figure S2). The
composition of these two sub-clusters is summarized in supple-
mental Table S6. The luminal-like sub-cluster is defined by over-
expression of the luminal markers ESR1, PGR and GATA3
[26,27,28] in all of its tissues and by the over-expression of CTGF,
MMP2, AR, CFB, CD44, EPOR, CDKN1B, ETAA1, FGFR2,
TNFRSF10B, ERBB4, SCUBE2, FOXA1 and MUC1 in tissues
from cancers with lobular or mixed ductal-lobular histology.
Except for AR [29] and ESR1 [30], none of these genes can be
linked to lobular cancer histology, in particular the comparison by
Zhao et al. of ductal and lobular carcinomas [31]. The role of
GATA3 for the maintenance of the luminal phenotype has been
reviewed by Tlsty, particularly the correlation of low expression of
GATA3 and low estrogen receptor alpha [32] which the present
data confirm. The basal-like sub-cluster, characterized by the
under-expression of these genes, is enriched for triple-negative
(hormone receptor and HER2-negative) cancers and contains all
cancer tissues of patients that are deceased (black dots) or have
recurred (orange dots). Lobular breast carcinomas are known to be
associated with better survival than ductal carcinomas [30,33] and
triple-negative breast cancers have been associated with poor
prognosis [34]. Also, in a meta-analysis of published breast cancer
cDNA data, low GATA3 expression is linked with poor clinical
outcome [35]. The difference between these cancer sub-clusters
could therefore be attributed to the aggressiveness of the disease.
Supporting this idea is the fact that the one lobular cancer tissue in
the basal-enriched cluster comes from a deceased patient (patient
26), which would infer that severity of outcome supersedes
histology.
The genes with over-expression in cancers with favorable as
opposed to those with poor outcome are listed in Figure 1 under
‘‘mixed expression’’ on the left. While some of these genes have
been linked to the basal subtype [7,10] and some are now being
used to predict disease outcome, including SCUBE2 in Oncotype
DX [36] and Mammaprint [37], the majority of them may
constitute a novel group of genes that predict outcome and/or
Breast Markers
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over-expressed in the cancers with poor outcome compared to
both cancers with favorable outcome and healthy controls
warranting further investigation as potential blood markers for
early detection of cancers with poor outcome.
In summary, the majority of the genes that distinguish cancers
by outcome are expressed at lower levels in tissues with poor than
in those with favorable outcome. Interestingly, these same genes
are also under-expressed in most controls, suggesting that, by and
large, molecular profiles might not be able to distinguish aggressive
breast cancer from healthy breast tissue. This suggests that these
genes have no potential as markers for the detection of aggressive
breast cancer, but they hold potential as prognostic markers.
Histologically Normal Tissues from an Affected Breast
Can Demonstrate Molecular Predisposition to Cancer
Unsupervised cluster analysis of the original PCR data placed 7
of the 38 ipsilateral normal tissues in the cancer cluster (Figure 1).
Figure 1. Unsupervised hierarchical clustering of 93 tissues and 67 genes. Unsupervised hierarchical clustering of 93 tissues (24 invasive
cancers, 38 ipsilateral normal, 3 contralateral normal, 28 normal tissues from reduction mammaplasty) from 64 patients and 67 genes that
discriminate between invasive tissues and mammaplasty normal tissues (red and green dots: over- and under-expression by PCR). Columns: tissues
form two distinct clusters (indicated below the figure). Rows: genes form a cancer and a normal cluster, the latter being divided in one with under-
expression in all cancer tissues (left, green line) and one with mixed expression (orange-blue line). Luminal-like and basal-like clusters are indicated
above the figure. The part of the heat map driving the luminal-like cluster is boxed (blue: luminal-like genes, turquoise: lobular tissues). Tissues from
deceased or recurred patients have a black or orange dot above the tissue descriptor which has the following abbreviated components: PatientNo –
Diagnosis (IDC=invasive ductal carcinoma, ILC=invasive lobular carcinoma, MET=metaplastic carcinoma, MUC=mucinous carcinoma,
NML=normal) – Stage – Grade TissueNo – Description (CA=cancer, NM=normal mammaplasty, NI=normal ipsilateral, NC=normal contralateral)
BI-RADS Density Subtype (LUM=luminal, BAS=basal HER2). The tissue descriptors are shaded as follows: orange=lobular cancers, pink=other
cancers, green=ipsilateral normals, blue=contralateral normals, purple=mammaplasty normals. Heat map: Red=up-regulation, green=down-
regulation, grey=missing or zero value. The lines below the heat map connect tissues from the same patient.
doi:10.1371/journal.pone.0009122.g001
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tissues cannot be correlated with tissue or patient characteristics
(supplemental Tables S1 and S2). Because BRCA status was not
recorded, the study does not address any possible link between
mutation and a cancer-like gene expression pattern in ipsilateral
normal tissue. Another explanation is a positional effect related to
distance between lesion and the site of normal tissue collection or
that index lesion and ipsilateral normal tissue come from the same
lobe [38]. Consequently, a normal tissue from an unaffected
contralateral breast should display a normal-like gene expression
pattern. Indeed, of the three contralateral normal tissues, the two
coming from a breast without evidence of cancer were found in the
normal cluster and the third, from a breast with malignancy,
grouped with the cancers.
Tripathi et al. compared normal tissue from mammaplasty to
ipsilateral normal and breast tissue with in situ disease. They found
that global gene expression abnormalities exist in both normal
epithelium of breast cancer patients and early cancers [6]. The
results presented here go one step further by including same-
patient invasive tissues. This leads to the conclusion that ipsilateral
normal tissues with cancer-like gene expression are molecularly
predisposed to cancer. To validate these findings, BRCA status of
the patient and positional information of the tissue pieces
harvested from a breast would need to be recorded. Our tissue
collection protocol has been altered accordingly.
Conclusions
Our results suggest that many of the genes commonly attributed
to cancer pathways are expressed at lower levels in breast cancers
than in normal breast tissue, confirming and further extending
results by Tripathi et al. [6]. Furthermore, the genes that predict
aggressive phenotype in between-cancer comparisons are in their
majority not differentially expressed between aggressive cancers
and healthy controls. If serum assays commonly measure the
increase of a marker rather than its absence in cancer, our findings
would help explain the current lack of suitable blood markers for
breast cancer, particularly in patients with poor prognosis
malignancies. With the exception of three genes (MMP12,
S100A7 and SPP1) whose expression requires further validation,
we were unable to find markers with potential utility for the
detection of aggressive disease.
In spite of these shortcomings, our work resulted in the
identification of a number of differentially expressed genes,
including a minimum of 46 discriminating between cancer and
controls and 12 related to aggressive disease. These 46 also identify
regions of ipsilateral histologically ‘normal’ breast tissue are
predisposed to becoming malignant. Of all discovered genes,
those coding for proteins that are readily shed may be of interest
for serum marker evaluation, assuming a positive correlation
between transcript and protein expression and that the proteins
are shed into the blood. Markers that are over-expressed but not
Table 3. Genes resulting from the OpenArray analysis.
CSF1 2100% HADHA 277% TP53I3 262% SLC2A3 238%
EGR1 2100% MCC 277% ANPEP 254% SMPD1 238%
FLT1 2100% RELA 277% BAG1 254% TGFBI 238%
FOS 2100% BTG2 269% ILK 254% BNIP3 231%
NID1 2100% CNBP 269% ING1 254% CBLB 231%
SEPP1 2100% DHX8 269% PECAM1 254% DEGS1 231%
SRPX 2100% EPHA2 269% PIR 254% EGLN1 231%
TGFBR2 2100% GNB2L1 269% RIPK1 254% ETV6 231%
TGFBR3 2100% IGFBP4 269% SFRS7 254% FOSL2 231%
TIE1 2100% NDRG1 269% TSG101 254% LDHA 231%
VIM 2100% PAQR3 269% CAPNS1 246% NR1D1 231%
HYAL1 292% PEA15 269% CHPT1 246% PRKCD 231%
PPARG 292% PFDN5 269% EIF5 246% PRNP 231%
RAB5A 292% RAF1 269% GTF2I 246% SORT1 231%
SEMA3C 292% RAP1A 269% JAK1 246% TRADD 231%
SPRY2 292% SKI 269% MDM2 246% EVL 31%
CCND3 285% SP1 269% MLLT10 246% HSPB1 31%
CDC42BPA 285% STK3 269% SELENBP1 246% KIF3B 38%
CIRBP 285% CSF1R 262% ATP5B 238% PKM2 38%
FOXO1 285% GAS6 262% AXL 238% RFC4 38%
ITGB3 285% NF2 262% CTNNA1 238% RARA 46%
PTEN 285% PECI 262% DCN 238% RAD21 54%
RHOB 285% PRKCE 262% EXT1 238% PRC1 77%
TYRO3 285% STAT3 262% HRB 238% SKIL 77%
ABL1 277% TAF1 262% PPP2R5A 238%
CD59 277% TJP1 262% PRKD2 238%
List of the 102 genes from the OpenArray analysis and percentage of tumor tissues they were differentially expressed in. Negative numbers indicate under-expression.
doi:10.1371/journal.pone.0009122.t003
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including prognosis.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of Fred Hutchinson Cancer Research
Center (IRB#5317), Cedars Sinai Cancer Center (IRB#4321/
CR00002187) and Swedish Medical Center (IRB#3992C-03). All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Patients and Tissues
Patients were enrolled at Swedish Medical Center, Seattle and
Cedars Sinai Medical Center, Los Angeles. Patients were consented
before surgery and administered a health status and family history
questionnaire. Hospital records were used for follow-up. Patient
characteristics are reported in the supplemental Table S1. Cancer,
ipsi- and contralateral normal tissues were obtained at Swedish
Medical Center from 44 patients (including 7 with neoadjuvant
treatment) undergoing mastectomy. Tissues from breast reduction
surgeries (20 patients) were obtained from private practices in Los
Angeles and histologically analyzed to exclude any with abnormal-
ities. In all cases, tissue was obtained and processed by research
personnel in the operating or gross room and frozen within 1 hour
of surgery. The frozen tissue available for research (mean: 150 g,
range: 20–500 g) was split into several pieces of which one was fixed
in formalin, embedded in paraffin and used for histological
examination by a pathologist. The other pieces were kept frozen
and used for RNA extraction. No microdissection was performed.
Viable tumor cell content in the cancer tissues varied from 15% to
95%, the rest being mostly fibrous and fatty tissue (Supplemental
Table S2). We did not selecttissues withmorethan 60%fatcontent.
The variability in tumor cell volume is a consequence of our
collection procedure where samples were taken from various
distances to the maintumor mass. Furthermore, lobular carcinomas
(25% of our cancer tissues) often display low tumor cellularity.
Unsupervised cluster analysis of these tissues showed no cluster
formation based on tumor cell content (Supplemental Figure S2). In
the end, gross and microscopic clinical evaluation matched the
histology of the actual tissue piece being analyzed in 50% of the
cancer tissues and 67% of tissues with normal histology.
LevelsDB
Over the last 10 years a database has been compiled (LevelsDB)
that holds gene and protein expression information from over 134
publications (90% transcript-, 10% protein-based) and 21,890
genes. LevelsDB was created to facilitate the discovery of markers
for cancer detection, and emphasis was given to publications with
data for normal controls as well as cancers. LevelsDB uses the
GeneID as an identifier [39] which is related to the gene symbols
governed by the Guidelines for Human Gene Nomenclature [40].
The datasets were extremely variable in the way they recorded
expression, ranging from a simple list of proteins to raw cDNA
microarray expression data. As a consequence, LevelsDB forewent
exact representation of original expression values. Instead, it
recorded whether or not a transcript or protein was present in a
given tissue, whether it had tumor-to-normal ratios above a factor
2 or, in the case of cDNA microarray-based expression data,
whether a mRNA was expressed at low, medium or high levels
(threshold defined by 1x, 3x, and 10x the median expression across
all tissues). LevelsDB also contains data on subcellular localization.
The datasets used in LevelsDB are listed in the supplemental
Document S1. Access to this database is available upon request.
RNA Extraction and Real-Time PCR (SYBR)
Snap-frozen tissues were homogenized with a TissueLyser
(Qiagen, Valencia, CA) in Trizol (Invitrogen, Carlsbad, CA).
Total RNA was then extracted using RNeasy with DNAse I
(Qiagen). RNA quality was measured by Agilent 2100 Bioanalyzer
(Agilent, Santa Clara, CA) to have a 28S/18S RNA ratio of 160.2
and by spectrophotometer with an OD260/OD280 ratio .1.6).
Mean total RNA yield was 906130 mg per mg of tissue. Copy
DNA was reverse transcribed from 5 mg of total RNA (Superscript
III kit, Invitrogen) with oligo-dT priming, of which 50 ng were
used as template in a 15 ml PCR. Copy DNA was amplified using
the SYBR green kit (Invitrogen) on a 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA). Each 384-well
plate contained aliquots of all cDNAs used during the experiment
as well as a standard made with testes cDNA in 5 dilutions (1:1,
1:3, 1:9, 1:27, 1:81) as duplicates, amplified with primers for ACTB
(all cDNAs were sub-aliquoted and stored at 220uC for
consistency). This allowed us to transform the logarithmic cycle
threshold (CT) values into linear values. Reactions were performed
in duplicate or, if samples did not amplify well or if the correlation
between the runs was poor, in triplicate. All PCRs were
normalized by the averaged expression of three housekeeping
genes ACTB, B2M and TMED10 run in triplicate. Primer
sequences are listed in the supplemental Document S3.
OpenArray Transcript Expression
Two micrograms of total RNA were reverse transcribed using
the High Capacity cDNA RT Kit (Applied Biosystems) with
random hexamer primers. All cDNA was analyzed on the Cancer
Pathways OpenArray system (BioTrove, Woburn, MA) using the
Fast Start DNA SYBR Green kit (Roche, Nutley, NJ). Four cDNA
samples were tested simultaneously per plate, with 16 samples per
run. CT values were transformed into linear values by calculating
1.735
‘ (32 - CT). Values were normalized by the mean of 18
housekeeping genes. The expression values from the OpenArray
platform and the qPCR (SYBR) were mean-normalized to allow
for comparison across the two platforms.
Cluster Analysis
Unsupervised hierarchical clustering was performed using
Spearman rank correlation as similarity metric and centroid
linkage as clustering method. PCR expression values were
averaged between duplicate runs, mean-normalized and entered
into the Cluster program [41] as log2 values. The tree was
visualized using Java Treeview [42].
Supporting Information
Document S1 List of the datasets used in LevelsDB and
references for the 134 potential marker genes.
Found at: doi:10.1371/journal.pone.0009122.s001 (0.06 MB
RTF)
Document S2 PCR expression data of the 134 genes in 93
tissues including explanation of the data processing.
Found at: doi:10.1371/journal.pone.0009122.s002 (0.06 MB
CSV)
Document S3 Primer sequences for the genes amplified the
qPCR.
Found at: doi:10.1371/journal.pone.0009122.s003 (0.01 MB
CSV)
Breast Markers
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9122Table S1 Characteristics of the 64 patients who donated tissue.
Age at diagnosis, Diagnosis (IDC=invasive ductal carcinoma,
ILC=invasive lobular carcinoma, MET=metaplastic carcinoma,
INF=inflammatory carcinoma, MUC=mucinous carcinoma,
NML=normal), Stage, grade and tumor size noted during gross
histopathological examination, Number of positive lymph nodes
out of all tested, BI-RADS mammography score (1=normal,
2=benign, 3= probably benign, 4= suspicious, 5=malignant),
Breast Density score (0=fatty, 1=average, 2=dense, 3=very
dense), Race (White, Black, Hispanic, Asian), Hormone receptor
(estrogen and/or progesterone) and ERBB2 status, and the tissue(s)
used (NI=normal ipsilateral, CA=invasive cancer, NC=normal
contralateral, NM=normal from mammaplasty; fatty=20-50%
fat). Progression-free survival (PFI) and survival given in months.
NED=no evidence of disease. Empty cells: no information. It
should be noted that the breast reduction population was 15 years
younger than the breast cancer population.
Found at: doi:10.1371/journal.pone.0009122.s004 (0.47 MB
PDF)
Table S2 Tissue Characteristics. Histopathological examination
was performed on the tissue piece adjacent to the one used for RNA
extraction. Patient numbers in the first column match those in table
S1. Tissue classification is explained in table S1. In the case of tumor
tissue, the histology lists the percentage of the tissue specimen that
wasinvolvedbytumor.Thepercentageofviabletumorcells,necrosis
and the inflammatory component within the tumor histology is listed
in the last three columns. These numbers donE ˆJt add up to 100%
as we did not record the percentage of fibrous or fatty tissue.
However, we limited collection of all tissues to those with less than
60% fat. Please note that tumor grade of an individual tissue piece
might differ from the grade of the entire tumor listed in table S1.
Found at: doi:10.1371/journal.pone.0009122.s005 (0.31 MB
PDF)
Table S3 List of the 134 genes (by gene symbol) found by
mining of expression data and/or LevelsDB mining (asterisk).
References are listed in the Supplement. The 8 genes for which
PCR was inconclusive are struck through. Thresholds for the
cancers and controls were determined by the expression in the 28
normal mammaplasty tissues as mean +3 SD for genes with over-
expression in the cancers and as below the minimum for genes
with under-expression in the cancers. These cutoff values lie well
above the gene expression variability in normal breast tissues listed
in Table 1. Columns 2 and 3 list the percent of cancer or control
tissues above or below this threshold. Result column: over- or
under-expression in cancer tissue for genes with .=20% of the
cancers and ,=5% of the controls above or below threshold.
Found at: doi:10.1371/journal.pone.0009122.s006 (0.06 MB
PDF)
Table S4 Comparison of PCR results from the original PCR
and the OpenArray results from the reduced tissue and gene set.
Listed are the expression values for the tumors (pink and orange
shading in the leftmost column) and the mammaplasty normal
controls (green shading) for both the original (TOR) and the
OpenArray platform (BT). The yellow- and purple-shaded cells
represent genes with over- and under-expression respectively. Due
to the extreme low number of control tissues (9), values with high
error (outliers) have a huge influence on the cutoff and hence the
overall results. Four of these outliers were removed (empty cells).
Found at: doi:10.1371/journal.pone.0009122.s007 (0.25 MB
PDF)
Table S5 PercentCVvaluesof originalandunfiltered OpenArray
PCR results. Percent CV values for all tissues (%CV a) and for only
those tissues with outliers were removed from the OpenArray results
(%CV b). Removal was acceptable because the OpenArray PCR
wasnotduplicatedliketheoriginalPCRandhadahighernumberof
values close or below the PCRE ˆJs detection limit.
Found at: doi:10.1371/journal.pone.0009122.s008 (0.04 MB
PDF)
Table S6 Composition of the Sub-Cluster of the Cancer Cluster.
Shown are the number of patients and the percentage of the total
number of patients per cluster. Highlighted are the features that
give the patients in the luminal-enriched cluster a better prognosis.
Found at: doi:10.1371/journal.pone.0009122.s009 (0.03 MB
PDF)
Figure S1 Unsupervised cluster analysis of the filtered Open-
Array data (112 genes, 13 invasive cancers and 9 normal control
tissues). The OpenArray dataset contains a high proportion of
genes with under-expression in the invasive cancer tissues (pink
shading on the left) compared to the healthy controls (green
shading on the left). The genes found to be under- or over-
expressed by the original dataset are indicated by a green or red
dot next to their names (right). These are found in the expected
cluster, further confirming the original PCR results. The tissue
descriptor above lists the histology (IDC in pink, ILC and IDLC in
orange and NML in green) followed by the tissue identifier.
Found at: doi:10.1371/journal.pone.0009122.s010 (0.23 MB
PDF)
Figure S2 Unsupervised cluster analysis of the 24 invasive
cancer tissues (7 tissues with .=60% and 17 with ,=30% viable
tumor cells) using the 67 genes that discriminate between invasive
tissues and mam- maplasty normal tissues. No cluster formation is
observed based on tumor cell content. The two clusters that are
formed separate the cancers by outcome.
Found at: doi:10.1371/journal.pone.0009122.s011 (0.24 MB
PDF)
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